Traders should monitor for upcoming full data readouts and potential partnerships or trial expansions; the current market cap of $59M may not reflect the potential value of these results if confirmed in larger trials.
PDSB drugs
PDSB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 15 $1.36entry
- T+1 · 7mo ago −5.88%α −6.14% · $1.28
- T+5 · 7mo ago −5.15%α −6.79% · $1.29
- T+20 · 6mo ago −19.12%α −25.16% · $1.10
- T+60 · 4mo ago −43.10%α −51.23% · $0.7739
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 78% objective response rate and over 80% two-year survival rate, compared to 35% and ~35% respectively in a parallel trial without PDS01ADC. These results suggest a potentially significant clinical improvement for the company's cancer therapy platform.
Key Facts
- PDS01ADC trial showed 78% objective response rate vs 35% in control arm
- Two-year survival rate exceeded 80% with PDS01ADC vs ~35% without
- Data appears to demonstrate strong efficacy signal for PDSB's ADC platform
Financial Impact
Potential revaluation of PDSB's platform given strong survival and response rates in early data
Risk Factors
- Data is preliminary and from a non-randomized parallel trial, raising potential selection bias
- Small sample sizes could skew response and survival rates
- Lack of regulatory approval path details or timeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3274455 |
Track record
28 reports on PDSB
7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 13 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
- Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
- Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
- Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
- Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
- Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers